1. Home
  2. LOAN vs LUNG Comparison

LOAN vs LUNG Comparison

Compare LOAN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • LUNG
  • Stock Information
  • Founded
  • LOAN 1989
  • LUNG 1995
  • Country
  • LOAN United States
  • LUNG United States
  • Employees
  • LOAN N/A
  • LUNG N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • LUNG Industrial Specialties
  • Sector
  • LOAN Real Estate
  • LUNG Health Care
  • Exchange
  • LOAN Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • LOAN 61.5M
  • LUNG 65.6M
  • IPO Year
  • LOAN 1999
  • LUNG 2020
  • Fundamental
  • Price
  • LOAN $5.37
  • LUNG $1.55
  • Analyst Decision
  • LOAN
  • LUNG Buy
  • Analyst Count
  • LOAN 0
  • LUNG 7
  • Target Price
  • LOAN N/A
  • LUNG $7.66
  • AVG Volume (30 Days)
  • LOAN 21.2K
  • LUNG 480.4K
  • Earning Date
  • LOAN 10-22-2025
  • LUNG 10-29-2025
  • Dividend Yield
  • LOAN 8.60%
  • LUNG N/A
  • EPS Growth
  • LOAN N/A
  • LUNG N/A
  • EPS
  • LOAN 0.48
  • LUNG N/A
  • Revenue
  • LOAN $7,300,469.00
  • LUNG $90,549,000.00
  • Revenue This Year
  • LOAN N/A
  • LUNG $10.30
  • Revenue Next Year
  • LOAN $4.47
  • LUNG $14.72
  • P/E Ratio
  • LOAN $11.15
  • LUNG N/A
  • Revenue Growth
  • LOAN N/A
  • LUNG 18.24
  • 52 Week Low
  • LOAN $4.74
  • LUNG $1.47
  • 52 Week High
  • LOAN $6.05
  • LUNG $9.37
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 49.82
  • LUNG 37.40
  • Support Level
  • LOAN $5.28
  • LUNG $1.60
  • Resistance Level
  • LOAN $5.44
  • LUNG $1.76
  • Average True Range (ATR)
  • LOAN 0.11
  • LUNG 0.13
  • MACD
  • LOAN 0.00
  • LUNG 0.02
  • Stochastic Oscillator
  • LOAN 75.00
  • LUNG 2.86

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: